Nature Reviews Disease Primers
In the recently completed phase III trial (CHABLISSC1) in patients with severe disease (SELENA-SLEDAI score 10), blisibimod showed a statistically significant steroid-sparing effect, reduction in SLE autoantibodies, B cell count, and proteinuria while increasing complement levels ( Atacicept is a fully human recombinant fusion protein made of the extracellular portion of the TACI receptor and the Fc portion of human IgG
a larger intramuscular (in the muscle) 22 gauge 1 inch needle
The elevated homocysteine creates further oxidative stress and neuroinflammation, which in turn damages the myelin sheath and worsens the cognitive dysfunction and neuropathy
Guo J, Huang X, Dou L, Yan M, Shen T, Tang W, Li J (2022) Aging and aging-related diseases: from molecular mechanisms to interventions and treatments